Publications (3)8.94 Total impact
-
Article: Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
[show abstract] [hide abstract]
ABSTRACT: This study aims to determine the effectiveness of paliperidone extended release (ER) on cognitive function in patients with schizophrenia in comparison with risperidone. This was a 12-week, randomized, open-label study on schizophrenia patients who were receiving risperidone. The patients were randomized to a risperidone-continuation group or a paliperidone-switch group. The primary outcome measure was neurocognitive function, which was measured using a computerized battery. Secondary efficacy measures included the Positive and Negative Syndrome Scale, Social and Occupational Functioning Scale, and Calgary Depression Scale for Schizophrenia. In total, 58 patients participated in this trial. Improvements in recall after an interference phase in the verbal learning test were significantly greater in the paliperidone-switch than in the risperidone-continuation group. No significant differences in changes were observed in the other six neurocognitive domains measured. Improvements in the Social and Occupational Functioning Scale were significantly greater in the paliperidone ER-switch group than in the risperidone-continuation group. In other efficacy outcome measures, no significant differences were observed between the two drugs. Paliperidone ER had a side-effect profile similar to that of risperidone, including metabolic problems and prolactin-related adverse events. In conclusion, switching from risperidone to paliperidone ER may lead to additional cognitive and social functional improvements.International clinical psychopharmacology 07/2012; 27(5):267-74. · 3.35 Impact Factor -
Article: Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia.
[show abstract] [hide abstract]
ABSTRACT: To examine changes in cognitive function and clinical features after a switch from atypical antipsychotics to aripiprazole in patients with schizophrenia. Sixty-one patients with schizophrenia treated with atypical antipsychotics participated in this open-label, 26-week study. Antipsychotics were switched to aripiprazole, and neurocognitive functions were measured at 12 and 26 weeks using the computerized battery. The secondary outcome measures were the Positive and Negative Syndrome Scale, the Social and Occupational Functioning Assessment Scale, the Calgary Depression Scale for Schizophrenia, the Subjective Well-being Under Neuroleptics Scale, and the Drug Attitude Inventory (DAI). The safety measures included metabolic parameters, the Simpson-Angus Rating Scale, the Barnes Akathisia Scale, and the Abnormal Involuntary Movement Scale. Significant improvements in cognitive function were observed in the Verbal Learning Test, the Wisconsin Card Sorting Test, and the Trail Making Test part A after a switch to aripiprazole. Scores on the Positive and Negative Syndrome Scale, the Social and Occupational Functioning Assessment Scale, the DAI, the Simpson-Angus Rating Scale, and the Abnormal Involuntary Movement Scale were significantly improved. The metabolic parameters, including serum cholesterol levels, were also improved. The changes in cognitive measures were not correlated with the changes in positive symptoms or movements scales. The improvement of the scores on the DAI and the delayed recall of the Verbal Learning Test were significantly greater in the patients treated with antipsychotics for less than 1 year than in those treated for more than 1 year, in whom the improvement in metabolic parameters was significantly greater. Patients with schizophrenia who switched from their previous antipsychotics to aripiprazole demonstrated improvements in cognitive function, psychotic symptoms, social function, attitude toward medication, and metabolic abnormalities.Clinical neuropharmacology 07/2009; 32(5):243-9. · 2.35 Impact Factor -
Article: Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial.
[show abstract] [hide abstract]
ABSTRACT: To determine the effectiveness of amisulpride on depression in patients with schizophrenia, in comparison to risperidone. In this open-label, 12-week study, patients with stable schizophrenia and a comorbid major or minor depressive episode (DSM-IV) taking risperidone were randomized into a risperidone-continuation group (N = 45) or an amisulpride-switch group (N = 42). The main outcome measures were changes from baseline on the Calgary Depression Scale for Schizophrenia (CDSS) and the Beck Depression Inventory (BDI). Secondary efficacy measures included the Positive and Negative Syndrome Scale (PANSS), and the Global Assessment of Functioning. Safety measures included treatment-emergent adverse events and extrapyramidal symptoms. The mean dose at endpoint was 4.2 mg/day for risperidone and 458.3 mg/day for amisulpride. Improvements in the CDSS and BDI scores were significantly greater in the amisulpride-switch group than in the risperidone-continuation group at weeks 8 and 12, and at the endpoint. The amisulpride-switch group also showed a significantly greater reduction in the score for the PANSS depression/anxiety factor, and the total score from baseline to endpoint. No significant difference was observed between the two groups for treatment-emergent adverse events or change from baseline for extrapyramidal symptoms. Switching from risperidone to amisulpride in patients with stable schizophrenia with comorbid depression improved depressive symptoms significantly compared to continuing with risperidone.Progress in Neuro-Psychopharmacology and Biological Psychiatry 11/2007; 31(7):1504-9. · 3.25 Impact Factor
Top co-authors
Top Journals
Institutions
-
2007–2012
-
Chonnam National University Hospital
Seoul, Seoul, South Korea
-
